The DOI matches its Crossref record; 287 of the 287 references it cites were found in a registry or an index.
An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease
Abstract
Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory disorders of the gastrointestinal tract. Collectively they are termed inflammatory bowel disease (IBD) and it is estimated that 1.5 million Americans (1) suffer from UC and CD. Their etiologies are unknown, although both are thought to arise from a disordered immune response to the gut contents in genetically predisposed individuals (1). The characteristics of the inflammatory response are different, with CD typically causing transmural inflammation and occasionally associated with granulomas, whereas in UC the inflammation is usually confined to the mucosa. Both UC and CD exhibit a relapsing and remitting course and there is a significant, often dramatic, reduction in quality of life during exacerbations of the disease (2). This has an impact on psychological health, with active IBD patients experiencing greater levels of distress and feelings of lack of sense of self-control compared with the normal population and patients with inactive IBD (3,4). Extrapolation from US administrative claims databases suggests that IBD is responsible for 2.3 million physician visits (5), 180,000 hospital admissions (6), and costs $6.3 billion (7) annually. There have been recent guidelines on the management of both UC (8) and CD (9) that direct the clinician on diagnosis and treatment. Approximately 33% of the cost of IBD is due to medical therapy (7), and given the substantial clinical burden and economic cost of IBD it is important to establish the effectiveness of current medical therapies in both UC and CD. Although there have been several systematic reviews on the efficacy of therapy (10,11), this is a rapidly changing field and there is a need for a comprehensive review of the literature. The American College of Gastroenterology IBD Task Force developed a protocol for systematically reviewing the data on currently available therapies for UC and CD, both in inducing remission and in preventing relapse of the disease. Evidence-based statements were then developed and the strength of recommendation for each was graded according to standard criteria. Section 1 Epidemiology of IBD Multiple studies have evaluated the epidemiology of IBD in adults from various geographic regions; most studies are from Western countries, where the incidence of IBD is highest, the existence of comprehensive databases is more common, and identification of adequately sized populations is easier (12). We have reviewed the literature on population estimates of CD and UC incidence over the past 20 years. Where there was more than one study we have taken the study with the largest population, which is most representative of the country. In the case of two studies of similar size we have evaluated the most recent data. We identified 35 studies (13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47) that provided data on incidence of CD and/or UC. In the US estimates of CD, incidence varies between 6 (13) and 8 (14) per 100,000, with a prevalence of 100 (13) to 200 (12) per 100,000. For UC, the incidence in the United States ranges between 9 (14) and 12 (13), with a prevalence of 205 (13) to 240 (12) per 100,000. Incidence estimates for other countries are given in Table 1. Geographical variation suggests that CD has a higher incidence in industrialized countries and higher rates in the West than in the East (Figure 1a). There also appears to be a North–South gradient with a strong correlation between degrees latitude and CD incidence when the Western Hemisphere and Western Europe are evaluated (Figure 2a). This North–South gradient also exists within an individual country, with CD being less common in the southern United States (12) and in the south of France (32). CD also has a high incidence in New Zealand, suggesting that the disease more common the the is from the There be an to CD that is more in a more similar exists for UC (Figure although the North–South gradient is (Figure Incidence of CD and UC variation in incidence rates for inflammatory bowel disease. Incidence rates for Crohn's disease. Incidence rates for ulcerative per in inflammatory bowel disease incidence rates with degrees latitude from the in Crohn's disease incidence in ulcerative colitis incidence has been in incidence over in most countries (Figure although it to have a in the United States and the Incidence rates are also over for UC, although the of is less (Figure rates to have a in the United States This be due to of is more to a in the that to CD. The of this in inflammatory bowel disease incidence rates over Incidence of Crohn's disease over Incidence of ulcerative colitis over of for CD has been although the disease be The diagnosis of UC also most of and then the incidence Western studies that CD is more common in with a of and a on of CD is a an between and CD in the in is a in the West and in the East CD be more common in The incidence of UC h
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
A human gut microbial gene catalogue established by metagenomic sequencing
MetaHIT Consortium, Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., et al. (2010) · Nature · doi:10.1038/nature08821 · Cited by 11,624
Hay fever, hygiene, and household size.
Strachan, D. P. (1989) · BMJ · doi:10.1136/bmj.299.6710.1259 · Cited by 5,054
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Self-citationInfliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902
Self-citationInfliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Colombel, J. F., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A., Rachmilewitz, D., Lichtiger, S., D'Haens, G., Diamond, R. H., Broussard, D. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904492 · Cited by 3,143
Self-citationTargan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Self-citationCoated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis
Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712243172603 · Cited by 3,026
Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,752
Self-citationAbraham, C., & Cho, J. H. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804647 · Cited by 2,712
Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach
Manichanh, C., Rigottier-Gois, L., Bonnaud, E., Gloux, K., Pelletier, E., Frangeul, L., Nalin, R., Jarrin, C., Chardon, P., Marteau, P., et al. (2006) · Gut · doi:10.1136/gut.2005.073817 · Cited by 2,277
Colombel, J., Sandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Panaccione, R., Schreiber, S., Byczkowski, D., Li, J., Kent, J. D., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.041 · Cited by 2,245
Self-citationInfliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,226
Self-citationKornbluth, A., & Sachar, D. B. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.727 · Cited by 2,023
Hanauer, S. B., Sandborn, W. J., Rutgeerts, P., Fedorak, R. N., Lukas, M., MacIntosh, D., Panaccione, R., Wolf, D., & Pollack, P. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.030 · Cited by 1,715
Self-citationCyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy
Lichtiger, S., Present, D. H., Kornbluth, A., Gelernt, I., Bauer, J., Galler, G., Michelassi, F., & Hanauer, S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406303302601 · Cited by 1,714
Self-citationInteractions between commensal intestinal bacteria and the immune system
Macpherson, A. J., & Harris, N. L. (2004) · Nature Reviews Immunology · doi:10.1038/nri1373 · Cited by 1,610
Darfeuille-Michaud, A., Boudeau, J., Bulois, P., Neut, C., Glasser, A.-L., Barnich, N., Bringer, M.-A., Swidsinski, A., Beaugerie, L., & Colombel, J.-F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.061 · Cited by 1,566
National Cooperative Crohn's Disease Study: Results of drug treatment
Summers, R. W., Switz, D. M., Sessions, J. T., Becktel, J. M., Best, W. R., Kern, F., & Singleton, J. W. (1979) · Gastroenterology · doi:10.1016/0016-5085(79)90385-8 · Cited by 1,239
D'Haens, G., Baert, F., van Assche, G., Caenepeel, P., Vergauwe, P., Tuynman, H., De Vos, M., van Deventer, S., Stitt, L., Donner, A., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60304-9 · Cited by 1,231
D’Haens, G., Sandborn, W. J., Feagan, B. G., Geboes, K., Hanauer, S. B., Irvine, E. J., Lémann, M., Marteau, P., Rutgeerts, P., Schölmerich, J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.12.038 · Cited by 1,207
Self-citationHench, P. S., Kendall, E. C., Slocumb, C. H., & Polley, H. F. (1949) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00526-3 · Cited by 1,179
Management of Crohn's Disease in Adults
Lichtenstein, G. R., Hanauer, S. B., & Sandborn, W. J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.168 · Cited by 1,173
Self-citationCertolizumab Pegol for the Treatment of Crohn's Disease
Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P. J., Rutgeerts, P., Mason, D., Bloomfield, R., & Schreiber, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067594 · Cited by 1,143
Self-citationJärnerot, G., Hertervig, E., Friis-Liby, I., Blomquist, L., Karlén, P., Grännö, C., Vilien, M., Ström, M., Danielsson, Å., Verbaan, H., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.003 · Cited by 1,089
Rutgeerts, P., D'Haens, G., Targan, S., Vasiliauskas, E., Hanauer, S. B., Present, D. H., Mayer, L., Van Hogezand, R. A., Braakman, T., DeWoody, K. L., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70332-x · Cited by 1,080
Self-citationThe Natural History of Adult Crohn's Disease in Population-Based Cohorts
Peyrin-Biroulet, L., Loftus, E. V., Colombel, J.-F., & Sandborn, W. J. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.579 · Cited by 1,047
Self-citationMaintenance Therapy with Certolizumab Pegol for Crohn's Disease
Schreiber, S., Khaliq-Kareemi, M., Lawrance, I. C., Thomsen, O. Ø., Hanauer, S. B., McColm, J., Bloomfield, R., & Sandborn, W. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062897 · Cited by 1,043
Self-citationTreatment of Crohn's Disease with 6-Mercaptopurine: A Long-Term, Randomized, Double-Blind Study
Present, D. H., Korelitz, B. I., Wisch, N., Glass, J. L., Sachar, D. B., & Pasternack, B. S. (1980) · New England Journal of Medicine · doi:10.1056/nejm198005013021801 · Cited by 1,042
Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial
Sandborn, W. J., Hanauer, S. B., Rutgeerts, P., Fedorak, R. N., Lukas, M., MacIntosh, D. G., Panaccione, R., Wolf, D., Kent, J. D., Bittle, B., et al. (2007) · Gut · doi:10.1136/gut.2006.106781 · Cited by 1,039
Self-citationTreatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α
Elliott, M. J., Maini, R. N., Feldmann, M., Long‐Fox, A., Charles, P., Katsikis, P., Brennan, F. M., Walker, J., Bijl, H., Ghrayeb, J., et al. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780361206 · Cited by 1,038
Shivananda, S., Lennard-Jones, J., Logan, R., Fear, N., Price, A., Carpenter, L., & van Blankenstein, M. (1996) · Gut · doi:10.1136/gut.39.5.690 · Cited by 1,028
Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease
Toruner, M., Loftus, E. V., Harmsen, W. S., Zinsmeister, A. R., Orenstein, R., Sandborn, W. J., Colombel, J., & Egan, L. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.012 · Cited by 1,017
Self-citationSandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Colombel, J.-F., Panaccione, R., D'Haens, G., Li, J., Rosenfeld, M. R., Kent, J. D., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00159 · Cited by 965
Self-citationEuropean Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment
Malchow, H., Ewe, K., Brandes, J. W., Goebell, H., Ehms, H., Sommer, H., & Jesdinsky, H. (1984) · Gastroenterology · doi:10.1016/0016-5085(84)90409-8 · Cited by 933
Kappelman, M. D., Rifas–Shiman, S. L., Kleinman, K., Ollendorf, D., Bousvaros, A., Grand, R. J., & Finkelstein, J. A. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.07.012 · Cited by 932
Natalizumab Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Colombel, J. F., Enns, R., Feagan, B. G., Hanauer, S. B., Lawrance, I. C., Panaccione, R., Sanders, M., Schreiber, S., Targan, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043335 · Cited by 927
Self-citationMethotrexate for the Treatment of Crohn's Disease
Feagan, B. G., Rochon, J., Fedorak, R. N., Irvine, E. J., Wild, G., Sutherland, L., Steinhart, A. H., Greenberg, G. R., Gillies, R., Hopkins, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502023320503 · Cited by 911
Self-citationSerious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry
Lichtenstein, G. R., Feagan, B. G., Cohen, R. D., Salzberg, B. A., Diamond, R. H., Chen, D. M., Pritchard, M. L., & Sandborn, W. J. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.03.002 · Cited by 905
Self-citationDe Bosscher, K., Vanden Berghe, W., & Haegeman, G. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0006 · Cited by 898
AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINE
Khan, A. K. A., Piris, J., & Truelove, S. C. (1977) · The Lancet · doi:10.1016/s0140-6736(77)90831-5 · Cited by 814
Natalizumab for Active Crohn's Disease
Ghosh, S., Goldin, E., Gordon, F. H., Malchow, H. A., Rask-Madsen, J., Rutgeerts, P., Vyhnálek, P., Zádorová, Z., Palmer, T., & Donoghue, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020732 · Cited by 808
Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
Yousry, T. A., Major, E. O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J., Curfman, B., Miszkiel, K., Mueller-Lenke, N., Sanchez, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054693 · Cited by 790
Smoking and Inflammatory Bowel Disease: A Meta-analysis
Mahid, S. S., Minor, K. S., Soto, R. E., Hornung, C. A., & Galandiuk, S. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.11.1462 · Cited by 774
A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease
Feagan, B. G., Fedorak, R. N., Irvine, E. J., Wild, G., Sutherland, L., Steinhart, A. H., Greenberg, G. R., Koval, J., Wong, C. J., Hopkins, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006013422202 · Cited by 727
Self-citationAn Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
American College of Gastroenterology IBS Task Force (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.122 · Cited by 694
Loftus, C. G., Loftus, E. V., Harmsen, S. W., Zinsmeister, A. R., Tremaine, W. J., Melton, J. L., & Sandborn, W. J. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20029 · Cited by 644
Self-citationThe Epidemiology of Inflammatory Bowel Disease in Canada: A Population-Based Study
Bernstein, C. N., Wajda, A., Svenson, L. W., MacKenzie, A., Koehoorn, M., Jackson, M., Fedorak, R., Israel, D., & Blanchard, J. F. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00603.x · Cited by 636
Self-citationClifford, D. B., DeLuca, A., Simpson, D. M., Arendt, G., Giovannoni, G., & Nath, A. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70028-4 · Cited by 636
Direct Health Care Costs of Crohn's Disease and Ulcerative Colitis in US Children and Adults
Kappelman, M. D., Rifas–Shiman, S. L., Porter, C. Q., Ollendorf, D. A., Sandler, R. S., Galanko, J. A., & Finkelstein, J. A. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.012 · Cited by 634
Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial
Targan, S. R., Feagan, B. G., Fedorak, R. N., Lashner, B. A., Panaccione, R., Present, D. H., Spehlmann, M. E., Rutgeerts, P. J., Tulassay, Z., Volfova, M., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.024 · Cited by 614
Self-citationEfficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Ford, A. C., Sandborn, W. J., Khan, K. J., Hanauer, S. B., Talley, N. J., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.73 · Cited by 604
Self-citationAzathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
Prefontaine, E., MacDonald, J. K., & Sutherland, L. R. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000545.pub3 · Cited by 604
Travis, S. P. L., Stange, E. F., Lémann, M., Öresland, T., Chowers, Y., Forbes, A., D’Haens, G., Kitis, G., Cortot, A., Prantera, C., et al. (2006) · Gut · doi:10.1136/gut.2005.081950b · Cited by 597
A Comparison of Budesonide with Prednisolone for Active Crohn's Disease
Rutgeerts, P., Lofberg, R., Malchow, H., Lamers, C., Olaison, G., Jewell, D., Danielsson, A., Goebell, H., Thomsen, O. O., Lorenz-Meyer, H., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409293311304 · Cited by 589
Schreiber, S., Rutgeerts, P., Fedorak, R. N., Khaliq–Kareemi, M., Kamm, M. A., Boivin, M., Bernstein, C. N., Staun, M., Thomsen, O. Ø., & Innes, A. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.06.064 · Cited by 580
Self-citationAntibiotic therapy in inflammatory bowel disease: A systematic review and meta-analysis
Khan, K. J., Ullman, T. A., Ford, A. C., Abreu, M. T., Abadir, A., Marshall, J. K., Talley, N. J., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.72 · Cited by 569
Self-citationA controlled double blind study of azathioprine in the management of Crohn's disease.
Candy, S., Wright, J., Gerber, M., Adams, G., Gerig, M., & Goodman, R. (1995) · Gut · doi:10.1136/gut.37.5.674 · Cited by 567
Oral Budesonide for Active Crohn's Disease
Greenberg, G. R., Feagan, B. G., Martin, F., Sutherland, L. R., Thomson, A., Williams, C. N., Nilsson, L.-G., & Persson, T. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409293311303 · Cited by 563
An Update on the Epidemiology of Inflammatory Bowel Disease in Asia
Thia, K. T., Loftus, Jr., Sandborn, W. J., & Yang, S.-K. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02158.x · Cited by 548
Self-citationEpidemiology of inflammatory bowel disease
Loftus, E. V., & Sandborn, W. J. (2002) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(01)00002-4 · Cited by 542
Self-citationCortisone in Ulcerative Colitis
Truelove, S. C., & Witts, L. J. (1954) · BMJ · doi:10.1136/bmj.2.4884.375 · Cited by 538
Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis
Timmer, A., Patton, P. H., Chande, N., McDonald, J. W., & MacDonald, J. K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000478.pub4 · Cited by 528
Double blind, placebo controlled trial of metronidazole in Crohn's disease.
Sutherland, L., Singleton, J., Sessions, J., Hanauer, S., Krawitt, E., Rankin, G., Summers, R., Mekhjian, H., Greenberger, N., & Kelly, M. (1991) · Gut · doi:10.1136/gut.32.9.1071 · Cited by 528
Self-citationFeller, M., Huwiler, K., Stephan, R., Altpeter, E., Shang, A., Furrer, H., Pfyffer, G. E., Jemmi, T., Baumgartner, A., & Egger, M. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70211-6 · Cited by 526
Infliximab for the treatment of fistulas in patients with Crohn's disease
Ricart, E., & Sandborn, W. J. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70414-2 · Cited by 519
Self-citationKeele, G. (1973) · The Lancet · doi:10.1016/s0140-6736(73)91022-2 · Cited by 499
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis
Wang, Y., Parker, C. E., Bhanji, T., Feagan, B. G., & MacDonald, J. K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000543.pub4 · Cited by 494
Yang, S.-K., Yun, S., Kim, J.-H., Park, J. Y., Kim, H. Y., Kim, Y.-H., Chang, D. K., Kim, J. S., Song, I. S., Park, J. B., et al. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20310 · Cited by 493
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
Wang, Y., Parker, C. E., Feagan, B. G., & MacDonald, J. K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000544.pub4 · Cited by 483
Economou, M., Trikalinos, T. A., Loizou, K. T., Tsianos, E. V., & Ioannidis, J. P. A. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.40304.x · Cited by 465
A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis
Ogata, H., Matsui, T., Nakamura, M., Iida, M., Takazoe, M., Suzuki, Y., & Hibi, T. (2006) · Gut · doi:10.1136/gut.2005.081794 · Cited by 462
Hanauer, S. B., Korelitz, B. I., Rutgeerts, P., Peppercorn, M. A., Thisted, R. A., Cohen, R. D., & Present, D. H. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.06.002 · Cited by 460
Self-citationRandomised controlled trial of azathioprine withdrawal in ulcerative colitis.
Hawthorne, A. B., Logan, R. F., Hawkey, C. J., Foster, P. N., Axon, A. T., Swarbrick, E. T., Scott, B. B., & Lennard-Jones, J. E. (1992) · BMJ · doi:10.1136/bmj.305.6844.20 · Cited by 452
Van Assche, G., D’haens, G., Noman, M., Vermeire, S., Hiele, M., Asnong, K., Arts, J., D’hoore, A., Penninckx, F., & Rutgeerts, P. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)01214-9 · Cited by 448
Animal Protein Intake and Risk of Inflammatory Bowel Disease: The E3N Prospective Study
Jantchou, P., Morois, S., Clavel-Chapelon, F., Boutron-Ruault, M.-C., & Carbonnel, F. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.192 · Cited by 426
Gradel, K. O., Nielsen, H. L., Schønheyder, H. C., Ejlertsen, T., Kristensen, B., & Nielsen, H. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.001 · Cited by 424
Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study
Sands, B. E., Tremaine, W. J., Sandborn, W. J., Rutgeerts, P. J., Hanauer, S. B., Mayer, L., Targan, S. R., & Podolsky, D. K. (2001) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200105000-00001 · Cited by 422
Self-citationLichtenstein, G. R., Abreu, M. T., Cohen, R., & Tremaine, W. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.01.048 · Cited by 417
Self-citationConcordance of Inflammatory Bowel Disease among Danish Twins: Results of a Nationwide Study
M. Orholm, V. B. (2000) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655200451207 · Cited by 404
Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease
Chande, N., Patton, P. H., Tsoulis, D. J., Thomas, B. S., & MacDonald, J. K. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000067.pub3 · Cited by 402
Dietary Risk Factors for Inflammatory Bowel Disease: A Multicenter Case-Control Study in Japan
Sakamoto, N., Kono, S., Wakai, K., Fukuda, Y., Satomi, M., Shimoyama, T., Inaba, Y., Miyake, Y., Sasaki, S., Okamoto, K., et al. (2005) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200502000-00009 · Cited by 398
D'Haens, G., Lemmens, L., Nevens, F., Hiele, M., Rutgeerts, P., Vandeputte, L., Peeters, M., Vermeire, S., Geboes, K., Van Acker, F., et al. (2001) · Gastroenterology · doi:10.1053/gast.2001.23983 · Cited by 393
LÉmann, M., Mary, J., Duclos, B., Veyrac, M., Dupas, J., Delchier, J. C., Laharie, D., Moreau, J., Cadiot, G., Picon, L., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.014 · Cited by 372
Lichtenstein, G. R., Sbreu, M. T., Cohen, R. D., & Tremaine, W. J. (2006) · PubMed · Cited by 371
Acute Gastroenteritis Is Followed by an Increased Risk of Inflammatory Bowel Disease
Rodríguez, L. A. G., Ruigómez, A., & Panés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.004 · Cited by 369
Brynskov, J., Freund, L., Rasmussen, S. N., Lauritsen, K., Muckadell, O. S. D., Williams, N., MacDonald, A. S., Tanton, R., Molina, F., Campanini, M. C., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198909283211301 · Cited by 369
Adalimumab for the treatment of fistulas in patients with Crohn’s disease
Colombel, J.-F., Schwartz, D. A., Sandborn, W. J., Kamm, M. A., D’Haens, G., Rutgeerts, P., Enns, R., Panaccione, R., Schreiber, S., Li, J., et al. (2009) · Gut · doi:10.1136/gut.2008.159251 · Cited by 365
Self-citationSVARTZ, N. (1942) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1942.tb06841.x · Cited by 364
Biological Therapies for Inflammatory Bowel Diseases
Rutgeerts, P., Vermeire, S., & Van Assche, G. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.001 · Cited by 363
Selby, W., Pavli, P., Crotty, B., Florin, T., Radford-Smith, G., Gibson, P., Mitchell, B., Connell, W., Read, R., Merrett, M., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.031 · Cited by 362
CONTROLLED TRIAL OF SULPHASALAZINE IN MAINTENANCE THERAPY FOR ULCERATIVE COLITIS
Misiewicz, J. J., Lennard-Jones, J. E., Connell, A. M., Baron, J. H., & Avery Jones, F. (1965) · The Lancet · doi:10.1016/s0140-6736(65)90972-4 · Cited by 360
Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial
Singleton, J. W., Hanauer, S. B., Gitnick, G. L., Peppercorn, M. A., Robinson, M. G., Wruble, L. D., & Krawitt, E. L. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90337-c · Cited by 357
Self-citationProbert, C. S. J., Hearing, S. D., Schreiber, S., Kühbacher, T., Ghosh, S., Arnott, I. D. R., & Forbes, A. (2003) · Gut · doi:10.1136/gut.52.7.998 · Cited by 355
Once-Daily, High-Concentration MMX Mesalamine in Active Ulcerative Colitis
Kamm, M. A., Sandborn, W. J., Gassull, M., Schreiber, S., Jackowski, L., Butler, T., Lyne, A., Stephenson, D., Palmen, M., & Joseph, R. E. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.10.011 · Cited by 352
Self-citationLémann, M., Mary, J.-Y., Colombel, J.-F., Duclos, B., Soule, J.-C., Lerebours, E., Modigliani, R., & Bouhnik, Y. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.031 · Cited by 349
Dissanayake, A. S., & Truelove, S. C. (1973) · Gut · doi:10.1136/gut.14.12.923 · Cited by 339
Sandborn, W. J., Present, D. H., Isaacs, K. L., Wolf, D. C., Greenberg, E., Hanauer, S. B., Feagan, B. G., Mayer, L., Johnson, T., Galanko, J., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00877-1 · Cited by 333
Self-citationDOUBLE-BLIND WITHDRAWAL TRIAL OF AZATHIOPRINE AS MAINTENANCE TREATMENT FOR CROHN'S DISEASE
O'Donoghue, D. P., Dawson, A. M., Powell-Tuck, J., Bown, R. L., & Lennard-Jones, J. E. (1978) · The Lancet · doi:10.1016/s0140-6736(78)92524-2 · Cited by 332
Azathioprine in Ulcerative Colitis: Final Report on Controlled Therapeutic Trial
Jewell, D. P., & Truelove, S. C. (1974) · BMJ · doi:10.1136/bmj.4.5945.627 · Cited by 332
Glucocorticosteroid Therapy in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Ford, A. C., Bernstein, C. N., Khan, K. J., Abreu, M. T., Marshall, J. K., Talley, N. J., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.70 · Cited by 328
Self-citationOral budesonide is as effective as oral prednisolone in active Crohn’s disease
Campieri, M., Ferguson, A., Doe, W., Persson, T., Nilsson, L.-G., & the Global Budesonide Study Group (1997) · Gut · doi:10.1136/gut.41.2.209 · Cited by 324
Hanauer, S. B., Sandborn, W. J., Kornbluth, A., Katz, S., Safdi, M., Woogen, S., Regalli, G., Yeh, C., Smith-Hall, N., & Ajayi, F. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.00248.x · Cited by 322
Self-citationA Population-Based Case Control Study of Potential Risk Factors for IBD
Bernstein, C. N., Rawsthorne, P., Cheang, M., & Blanchard, J. F. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00381.x · Cited by 315
Self-citationPicco, M. F. (2010) · Yearbook of Gastroenterology · doi:10.1016/s0739-5930(09)79399-7 · Cited by 315
CONTROLLED TRIAL OF AZATHIOPRINE IN CROHN'S DISEASE
Willoughby, J. M. T., Beckett, J., Kumar, P., & Dawson, A. M. (1971) · The Lancet · doi:10.1016/s0140-6736(71)90268-6 · Cited by 314
Gordon, F. H., Lai, C. W. Y., Hamilton, M. I., Allison, M. C., Srivastava, E. D., Fouweather, M. G., Donoghue, S., Greenlees, C., Subhani, J., Amlot, P. L., et al. (2001) · Gastroenterology · doi:10.1053/gast.2001.26260 · Cited by 314
The Risk of Oral Contraceptives in the Etiology of Inflammatory Bowel Disease: A Meta-Analysis
Cornish, J. A., Tan, E., Simillis, C., Clark, S. K., Teare, J., & Tekkis, P. P. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02064.x · Cited by 297
Oren, R., Arber, N., Odes, S., Moshkowitz, M., Keter, D., Pomeranz, I., Ron, Y., Reisfeld, I., Broide, E., Lavy, A., et al. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8613046 · Cited by 297
Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis
Ford, A. C., Achkar, J.-P., Khan, K. J., Kane, S. V., Talley, N. J., Marshall, J. K., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.67 · Cited by 295
Self-citationIncidence and prevalence of ulcerative colitis in Punjab, North India
Sood, A., Midha, V, Sood, N., Bhatia, A. S., & Avasthi, G. (2003) · Gut · doi:10.1136/gut.52.11.1587 · Cited by 294
Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease
Akobeng, A. K., Zhang, D., Gordon, M., & MacDonald, J. K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003715.pub3 · Cited by 289
Greenberg, G., Feagan, B., Martin, F., Sutherland, L., Thomson, A., Williams, C., Nilsson, L., & Persson, T. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8536887 · Cited by 288
SULPHASALAZINE AND SALICYLAZOSULPHADIMIDINE IN ULCERATIVE COLITIS
Baron, J. H., Connell, A. M., Lennard-Jones, J. E., & Avery Jones, F. (1962) · The Lancet · doi:10.1016/s0140-6736(62)92080-9 · Cited by 287
Thia, K. T., Mahadevan, U., Feagan, B. G., Wong, C., Cockeram, A., Bitton, A., Bernstein, C. N., & Sandborn, W. J. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20608 · Cited by 278
Self-citationEffects of glucocorticoids on gene transcription
Hayashi, R., Wada, H., Ito, K., & Adcock, I. M. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.07.011 · Cited by 277
High incidence of Crohnʼs disease in Canterbury, New Zealand: Results of an epidemiologic study
Gearry, R. B., Richardson, A., Frampton, C. M. A., Collett, J. A., Burt, M. J., Chapman, B. A., & Barclay, M. L. (2006) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000231572.88806.b9 · Cited by 273
Methotrexate for induction of remission in refractory Crohn's disease
McDonald, J. W., Wang, Y., Tsoulis, D. J., MacDonald, J. K., & Feagan, B. G. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003459.pub4 · Cited by 270
Lichtenstein, G. R., Kamm, M. A., Boddu, P., Gubergrits, N., Lyne, A., Butler, T., Lees, K., Joseph, R. E., & Sandborn, W. J. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.10.025 · Cited by 267
Self-citationHanauer, S., SCHWARTZ, J., ROBINSON, M. G., Roufail, W. M., Arora, S., Cello, J. P., & Safdi, M. A. (1993) · PubMed · Cited by 266
Self-citationBudesonide for induction of remission in Crohn's disease
Rezaie, A., Kuenzig, M. E., Benchimol, E. I., Griffiths, A. M., Otley, A. R., Steinhart, A. H., Kaplan, G. G., & Seow, C. H. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000296.pub4 · Cited by 260
West, R. L., van der Woude, C. J., Hansen, B. E., Felt‐Bersma, R. J. F., van Tilburg, A. J. P., Drapers, J. A. G., & Kuipers, E. J. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02247.x · Cited by 256
Probiotics for maintenance of remission in Crohn's disease
Rolfe, V. E., Fortun, P. J., Hawkey, C. J., & Bath-Hextall, F. J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004826.pub2 · Cited by 251
Sandborn, W. J., & Hanauer, S. B. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01408.x · Cited by 247
Self-citationKhan, K. J., Dubinsky, M. C., Ford, A. C., Ullman, T. A., Talley, N. J., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.64 · Cited by 246
Self-citationHanauer, S. B., & Strömberg, U. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00122-3 · Cited by 246
Self-citationControlled trial of sulphasalazine in the treatment of ulcerative colitis
Dick, A. P., Grayson, M. J., Carpenter, R. G., & Petrie, A. (1964) · Gut · doi:10.1136/gut.5.5.437 · Cited by 243
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease
Behm, B. W., & Bickston, S. J. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006893 · Cited by 239
The Epidemiology and Phenotype of Crohn’s Disease in the Chinese Population
Leong, R. W. L., Lau, J. Y., & Sung, J. J. Y. (2004) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200409000-00022 · Cited by 238
Population‐based cases control study of inflammatory bowel disease risk factors
Gearry, R. B., Richardson, A. K., Frampton, C. M., Dodgshun, A. J., & Barclay, M. L. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.06140.x · Cited by 237
Diet and Inflammatory Bowel Disease: A Case-Control Study
Persson, P.-G., Ahlbom, A., & Hellers, G. (1992) · Epidemiology · doi:10.1097/00001648-199201000-00009 · Cited by 236
TURUNEN, U., FARKKILA, M., HAKALA, K., SEPPALA, K., SIVONEN, A., OGREN, M., VUORISTO, M., VALTONEN, V, & MIETTINEN, T. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70076-9 · Cited by 229
Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis
Lawson, M. M., Thomas, A. G., & Akobeng, A. K. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005112.pub2 · Cited by 229
Lennard-Jones, J. E., Longmore, A. J., Newell, A. C., Wilson, C. W. E., & Jones, F. A. (1960) · Gut · doi:10.1136/gut.1.3.217 · Cited by 227
An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome
Brandt, L. J., Chey, W. D., Foxx-Orenstein, A. E., Quigley, E. M. M., Schiller, L. R., Schoenfeld, P. S., Spiegel, B. M., Talley, N. J., & Moayyedi, P. (2009) · American Journal of Gastroenterology · doi:10.14309/00000434-200901001-00002 · Cited by 225
Self-citationClark, M., Colombel, J.-F., Feagan, B. C., Fedorak, R. N., Hanauer, S. B., Kamm, M. A., Mayer, L., Regueiro, C., Rutgeerts, P., Sandborn, W. J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.006 · Cited by 224
Self-citationCorticosteroids for maintenance of remission in Crohn's disease
Steinhart, A. H., Ewe, K., Griffiths, A. M., Modigliani, R., & Thomsen, O. O. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000301 · Cited by 224
Efficacy of 5-Aminosalicylates in Crohn's Disease: Systematic Review and Meta-Analysis
Ford, A. C., Kane, S. V., Khan, K. J., Achkar, J.-P., Talley, N. J., Marshall, J. K., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.71 · Cited by 223
Self-citation5-Aminosalicylates and renal function in inflammatory bowel disease: A systematic review
Gisbert, J. P., González-Lama, Y., & Maté, J. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20099 · Cited by 220
Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease
Ewe, K., Press, A. G., Singe, C. C., Stufler, M., Ueberschaer, B., Hommel, G., & Büschenfelde, K.-H. M. Z. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90709-l · Cited by 217
Loftus, E. V., Feagan, B. G., Colombel, J.-F., Rubin, D. T., Wu, E. Q., Yu, A. P., Pollack, P. F., Chao, J., & Mulani, P. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02175.x · Cited by 217
Crohn's disease in Japan: Diagnostic criteria and epidemiology
Yao, T., Matsui, T., & Hiwatashi, N. (2000) · Diseases of the Colon & Rectum · doi:10.1007/bf02237231 · Cited by 217
Combined budesonide and antibiotic therapy for active Crohn's disease: A randomized controlled trial
Steinhart, A. H., Feagan, B. G., Wong, C. J., Vandervoort, M., Mikolainis, S., Croitoru, K., Seidman, E., Leddin, D. J., Bitton, A., Drouin, E., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.34225 · Cited by 216
Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.
Azad Khan, A. K., Howes, D. T., Piris, J., & Truelove, S. C. (1980) · Gut · doi:10.1136/gut.21.3.232 · Cited by 215
Budesonide versus prednisone in the treatment of active Crohn's disease
Bar–Meir, S., Chowers, Y., Lavy, A., Abramovitch, D., Sternberg, A., Leichtmann, G., Reshef, R., Odes, S., Moshkovitz, M., Bruck, R., et al. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70254-9 · Cited by 211
Hou, J. K., El-Serag, H., & Thirumurthi, S. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.190 · Cited by 211
Löfberg, R., Rutgeerts, P., Malchow, H., Lamers, C., Danielsson, A., Olaison, G., Jewell, D., Ostergaard Thomsen, O., Lorenz-Meyer, H., Goebell, H., et al. (1996) · Gut · doi:10.1136/gut.39.1.82 · Cited by 209
Adverse Events Associated With Common Therapy Regimens for Moderate-to-Severe Crohn's Disease
Marehbian, J., Arrighi, H. M., Hass, S., Tian, H., & Sandborn, W. J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.322 · Cited by 208
Self-citationSands, B. E., Kozarek, R., Spainhour, J., Barish, C. F., Becker, S., Goldberg, L., Katz, S., Goldblum, R., Harrigan, R., Hilton, D., et al. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20014 · Cited by 206
Self-citationThe Role of Microbes in Crohn's Disease
Eckburg, P. B., & Relman, D. A. (2007) · Clinical Infectious Diseases · doi:10.1086/510385 · Cited by 205
A controlled trial of azathioprine in Crohn's disease
Rosenberg, J. L., Levin, B., Wall, A. J., & Kirsner, J. B. (1975) · The American Journal of Digestive Diseases · doi:10.1007/bf01070829 · Cited by 201
Review article: mode of action and delivery of 5‐aminosalicylic acid – new evidence
DESREUMAUX, P., & GHOSH, S. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03069.x · Cited by 199
PARKINSON, T. (1947) · PubMed · Cited by 199
Probiotics for induction of remission in ulcerative colitis
Mallon, P. T., McKay, D., Kirk, S. J., & Gardiner, K. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005573.pub2 · Cited by 195
Crohn’s disease in Stockholm County during 1990-2001: An epidemiological update
Lapidus, A. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i1.75 · Cited by 192
Oren, R., Moshkowitz, M., Odes, S., et al. (1997) · PubMed · Cited by 189
Azodisal sodium in the treatment of ulcerative colitis
Sandberg-Gertzén, H., Järnerot, G., & Kraaz, W. (1986) · Gastroenterology · doi:10.1016/0016-5085(86)90882-6 · Cited by 187
Short‐term adverse effects of 5‐aminosalicylic acid agents in the treatment of ulcerative colitis
Loftus, E. V., Kane, S. V., & Bjorkman, D. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.0269-2813.2004.01827.x · Cited by 184
Self-citationCONTROLLED TRIAL OF AZATHIOPRINE IN CROHN'S DISEASE
Rhodes, J., Beck, P., Bainton, D., & Campbell, H. (1971) · The Lancet · doi:10.1016/s0140-6736(71)90598-8 · Cited by 184
Dickinson, R. J., O'Connor, H. J., Pinder, I., Hamilton, I., Johnston, D., & Axon, A. T. (1985) · Gut · doi:10.1136/gut.26.12.1380 · Cited by 184
Diet as a risk factor for the development of ulcerative colitis
Geerling, B. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)00734-6 · Cited by 182
Traditional corticosteroids for induction of remission in Crohn's disease
Benchimol, E. I., Seow, C. H., Steinhart, A. H., & Griffiths, A. M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006792.pub2 · Cited by 182
Cyclosporine A for induction of remission in severe ulcerative colitis
Shibolet, O., Regushevskaya, E., Brezis, M., & Soares-Weiser, K. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004277.pub2 · Cited by 182
Preliminary Study of Ciprofloxacin in Active Crohn's Disease
Arnold, G. L., Beaves, M. R., Pryjdun, V. O., & Mook, W. J. (2002) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200201000-00002 · Cited by 181
Nerich, V., Monnet, E., Etienne, A., Louafi, S., Ramée, C., Rican, S., Weill, A., Vallier, N., Vanbockstael, V., Auleley, G.-R., et al. (2006) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000206540.38834.8c · Cited by 180
Halfvarson, J., Jess, T., Magnuson, A., Montgomery, S. M., Orholm, M., Tysk, C., Binder, V., & Järnerot, G. (2006) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000228998.29466.ac · Cited by 175
Rahimi, R., Nikfar, S., Rahimi, F., Elahi, B., Derakhshani, S., Vafaie, M., & Abdollahi, M. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-007-0171-0 · Cited by 173
Crohn's disease: the cold chain hypothesis
Hugot, J.-P., Alberti, C., Berrebi, D., Bingen, E., & Cézard, J.-P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)15024-6 · Cited by 173
Mantzaris, G. J., Hatzis, A., Kontogiannis, P., & Triadaphyllou, G. (1994) · PubMed · Cited by 171
Sandborn, W. J., Regula, J., Feagan, B. G., Belousova, E., Jojic, N., Lukas, M., Yacyshyn, B., Krzeski, P., Yeh, C., Messer, C. A., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.08.069 · Cited by 169
Self-citationInfluence of inflammatory bowel disease on different dimensions of quality of life
Casellas, F., López-Vivancos, J., Badia, X., Vilaseca, J., & Malagelada, J.-R. (2001) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200105000-00017 · Cited by 168
The efficacy of tobramycin in the treatment of ulcerative colitis
BURKE, D. A., AXON, A. T. R., CLAYDEN, S. A., DIXON, M. F., JOHNSTON, D., & LACEY, R. W. (1990) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1990.tb00456.x · Cited by 166
Hanauer, S. B., Sandborn, W. J., Dallaire, C., Archambault, A., Yacyshyn, B., Yeh, C., & Smith-Hall, N. (2007) · Canadian Journal of Gastroenterology · doi:10.1155/2007/862917 · Cited by 164
Self-citationThe Risk of Developing Crohn's Disease After an Appendectomy: A Meta-Analysis
Kaplan, G. G., Jackson, T., Sands, B. E., Frisch, M., Andersson, R. E., & Korzenik, J. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02118.x · Cited by 164
The state of the art in the management of inflammatory bowel disease.
Hanauer, S. B., & Present, D. H. (2003) · PubMed · Cited by 163
Self-citationPRANTERA, C., LOCHS, H., CAMPIERI, M., SCRIBANO, M. L., STURNIOLO, G. C., CASTIGLIONE, F., & COTTONE, M. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02879.x · Cited by 163
Budesonide for maintenance of remission in Crohn's disease
Kuenzig, M. E., Rezaie, A., Seow, C. H., Otley, A. R., Steinhart, A. H., Griffiths, A. M., Kaplan, G. G., & Benchimol, E. I. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002913.pub3 · Cited by 160
Jacobsen, B. A., Fallingborg, J., Rasmussen, H. H., Nielsen, K. R., Drewes, A. M., Puho, E., Nielsen, G. L., & S??rensen, H. T. (2006) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200606000-00005 · Cited by 160
Herrinton, L. J., Liu, L., Lewis, J. D., Griffin, P. M., & Allison, J. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01960.x · Cited by 160
Mantzaris, G. J., Petraki, K., Archavlis, E., Amberiadis, P., Kourtessas, D., Christidou, A., & Triantafyllou, G. (2001) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655201750305503 · Cited by 160
Drug Insight: aminosalicylates for the treatment of IBD
Nielsen, O. H., & Munck, L. K. (2007) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0696 · Cited by 159
Treatment of Crohn's Disease with Azathioprine: A Controlled Evaluation
Klein, M., Binder, H. J., Mitchell, M., Aaronson, R., & Spiro, H. (1974) · Gastroenterology · doi:10.1016/s0016-5085(74)80166-6 · Cited by 158
Victoria, C. R., Sassak, L. Y., & Nunes, H. R. D. C. (2009) · Arquivos de Gastroenterologia · doi:10.1590/s0004-28032009000100009 · Cited by 156
Risk factors for inflammatory bowel disease in the general population
Rodríguez, L. A. G., González‐Pérez, A., Johansson, S., & Wallander, M.-A. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02564.x · Cited by 156
An Oral Preparation of Mesalamine as Long-Term Maintenance Therapy for Ulcerative Colitis
Hanauer, S. B., Sninsky, C. A., Robinson, M., Powers, B. J., McHattie, J. D., Mayle, J. E., Elson, C. O., DeMicco, M. P., Butt, J. H., Pruitt, R. E., et al. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-2-199601150-00003 · Cited by 155
Self-citationEuropean trial of cyclosporine in chronic active Crohn's disease: A 12-month study
Stange, E. F., Modigliani, R., Peña, A. S., Wood, A. J., Feutren, G., & Smith, P. R. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90384-4 · Cited by 152
Gendre, J., Mary, J., Florent, C., Modigliani, R., Colombel, J., Soulé, J., Galmiche, J., Lerebours, É., Descos, L., Viteau, J. M., et al. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90411-5 · Cited by 150
Gionchetti, P., Rizzello, F., Ferrieri, A., Venturi, A., Brignola, C., Ferretti, M., Peruzzo, S., Miglioli, M., & Campieri, M. (1999) · Digestive Diseases and Sciences · doi:10.1023/a:1026648812439 · Cited by 150
Modigliani, R., Colombel, J. F., Jl, D., Dapoigny, M. C., Costil, V., Veyrac, M., Duclos, B., Soulé, J. C., Jp, G., Jp, G., et al. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8608877 · Cited by 149
Natalizumab for induction of remission in Crohn's disease
MacDonald, J. K., & McDonald, J. W. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006097.pub2 · Cited by 148
A Population-based Ecologic Study of Inflammatory Bowel Disease: Searching for Etiologic Clues
Green, C. A., Elliott, L. J., Beaudoin, C. M., & Bernstein, C. N. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwj260 · Cited by 148
Self-citationTopical delivery of therapeutic agents in the treatment of inflammatory bowel disease
Klotz, U. E., & Schwab, M. G. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.08.007 · Cited by 147
Tremaine, W. J., Schroeder, K. W., Harrison, J. M., & Zinsmeister, A. R. (1994) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-199412000-00003 · Cited by 146
Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease
Akobeng, A. K., & Zachos, M. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003574.pub2 · Cited by 139
Ohkusa, T., Kato, K., Terao, S., Chiba, T., Mabe, K., Murakami, K., Mizokami, Y., Sugiyama, T., Yanaka, A., Takeuchi, Y., et al. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.84 · Cited by 138
Lakatos, L., Mester, G., Erdélyi, Z., Balogh, M., Szipócs, I., Kamarás, G., & Lakatos, P. L. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i3.404 · Cited by 138
Pentasa UC Maintenance Study Group, Miner, P. B., Hanauer, S. B., ROBINSON, M. G., Schwartz, J., & Arora, S. (1995) · Digestive Diseases and Sciences · doi:10.1007/bf02065413 · Cited by 135
Self-citationStress Coping, Distress, and Health Perceptions in Inflammatory Bowel Disease and Community Controls
Graff, L. A., Walker, J. R., Clara, I. P., Lix, L. M., Miller, N., Rogala, L., Rawsthorne, P. E., & Bernstein, C. N. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.529 · Cited by 135
Self-citationOral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease
Prantera, C., Pallone, F., Brunetti, G., Cottone, M., & Miglioli, M. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90822-g · Cited by 132
Cited by
Torres, J., Mehandru, S., Colombel, J.-F., & Peyrin-Biroulet, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31711-1 · Cited by 2,682
Baumgart, D. C., & Sandborn, W. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60026-9 · Cited by 2,154
Self-citationMoayyedi, P., Surette, M. G., Kim, P. T., Libertucci, J., Wolfe, M., Onischi, C., Armstrong, D., Marshall, J. K., Kassam, Z., Reinisch, W., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.001 · Cited by 1,499
Self-citationSunlight and Vitamin D: A global perspective for health
Wacker, M., & Holick, M. F. (2013) · Dermato-Endocrinology · doi:10.4161/derm.24494 · Cited by 1,156
Antibiotic therapy in inflammatory bowel disease: A systematic review and meta-analysis
Khan, K. J., Ullman, T. A., Ford, A. C., Abreu, M. T., Abadir, A., Marshall, J. K., Talley, N. J., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.72 · Cited by 569
Self-citation
Metadata
- Authors
- Talley, N. J., Abreu, M. T., Achkar, J.-P., Bernstein, C. N., Dubinsky, M. C., Hanauer, S. B., Kane, S. V., Sandborn, W. J., Ullman, T. A., & Moayyedi, P.
- Venue
- American Journal of Gastroenterology
- Published
- 2011-04
- Volume
- 106
- Pages
- S2-S25
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W1984426896
- Cited by
- 310
- References
- 287
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.